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Abstract 
Background: In Poland, multi-cause pneumonia is not well characterized, and there is limited pneumococcal vaccination in the 
youngest and oldest age groups. The goal of this study was to assess hospitalized pneumonia across all age groups in two Polish 
counties.
Material and methods: Using electronic administrative databases, cases were identified as county residents hospitalized at 
Chrzanów and Inowrocław County Hospitals from 2006–2008, assigned a diagnosis of pneumonia. Calculations by admission 
year, sex, and age category were: hospitalization rates per 1000 persons; in-hospital mortality rates per 100 persons; and median 
length of stay (LOS). 
Results: There were 1444 and 2956 hospitalizations for new episodes of pneumonia with rates of 3.76 (95% confidence interval 
[CI] 3.57–3.96) and 5.99 (95% CI 5.77–6.21) per 1000 persons in Chrzanów and Inowrocław counties, respectively. In combined 
data, the highest hospitalization rate was among patients aged 0–4 years (30.77; 95% CI 29.06–32.55) followed by those aged 
≥ 75 years (25.39; 95% CI 24.01–26.83). In-hospital mortality rates increased with age at both sites. The median LOS was 8 days.
Conclusions: Pneumonia hospitalizations were substantial, especially for the youngest and oldest age groups. Future public health 
interventions aimed at these age groups might improve disease outlook.
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Streszczenie 
Wstęp: Dane dotyczące etiologii zapaleń płuc w Polsce są skąpe, a wyszczepialność szczepionką pneumokokową wśród osób 
w najmłodszej i najstarszej grupie wiekowej — nieznaczna. Celem prezentowanego badania była ocena leczonego szpitalnie 
zapalenia płuc we wszystkich grupach wiekowych w dwóch powiatach Polski. 
Materiał i metody: W badaniu wykorzystano dane zawarte w elektronicznych szpitalnych bazach danych, dotyczące mieszkań-
ców powiatów, hospitalizowanych w Szpitalach Powiatowych w Chrzanowie i Inowrocławiu w latach 2006–2008, z rozpoznaniem 
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zapalenia płuc. Uzyskane wyniki: częstość hospitalizacji na 1000 osób, współczynnik śmiertelności w trakcie pobytu w szpitalu 
na 100 osób, mediana długości hospializacji, zgrupowano według roku przyjęcia, płci i wieku.
Wyniki: W Szpitalu Powiatowym w Chrzanowie stwierdzono 1444, a w Inowrocławiu 2956 przypadków hospitalizacji z niezależ-
nymi epizodami zapalenia płuc. Częstość hospitalizacji wyniosła 3,76 (95% przedział ufności [CI]: 3,57;3,96) i 5,99 (95% CI: 5,77; 
6,21) na 1000, odpowiednio dla powiatów chrzanowskiego i inowrocławskiego. W całej badanej grupie najwyższą częstość hospi-
talizacji obserwowano w grupie 0–4 lat (30,77 [95% CI: 29,06; 32,55]) oraz ≥ 75 lat (25,39 [95% CI: 24,01; 26,83]). Współczynnik 
śmiertelności w szpitalu w obu badanych ośrodkach wzrastał wraz z wiekiem. Mediana długości pobytu w szpitalu wyniosła 8 dni. 
Wnioski: Liczba hospitalizacji z powodu zapalenia płuc była znacząca, szczególnie w najmłodszej i najstarszej grupie wiekowej. 
Przyszłe działania opieki zdrowotnej skierowane do tych grup wiekowych mogą wpłynąć na zapadalność na zapalenie płuc oraz 
poprawić wyniki leczenia.
Słowa kluczowe: pozaszpitalne zapalenie płuc, częstość hospitalizacji, współczynnik śmiertelności, zakażenie pneumokokowe, 
badanie retrospektywne
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Introduction
Community-acquired pneumonia (CAP) is 
a major cause of morbidity and mortality. The 
highest incidence of CAP occurs among young 
children and older adults [1, 2], whereas mortality 
is highest among older adults [3]. 
CAP has frequently been found to be pneumo-
coccal in nature. One review of the burden of CAP 
in Europe, covering 41 prospective studies in 
a variety of age groups and populations, found 
that Streptococcus pneumoniae played a role in 
20–25% of cases, and was the most commonly 
identified causative agent [4]. Of note, in this 
review 40–50% of patients in studies had unspe-
cified CAP [4], whereas a similar study in England 
found even higher proportions [5]. However, 
because diagnostic specificity may not change 
treatment, and culture methods have limited sen-
sitivity, the proportion of CAP linked to pneumo-
coccal infection has been difficult to assess [5].
Two vaccine types for pneumococcal disease 
have been available in Poland: pneumococcal 
conjugate vaccine (PCV), which initially was in-
dicated only for infants and young children and 
latter approved for older adults, and 23-valent 
pneumococcal polysaccharide vaccine (PPSV23), 
which was recommended for older adults, chil-
dren above 2 years of age, and adults with condi-
tions that put them at high risk for pneumococcal 
disease [6–8]. Unlike many other European coun-
tries, Poland has not had universal pneumococcal 
vaccination for children < 2 years as part of its 
NIP [9]. In 2008, 7-valent PCV (PCV7) became 
available free-of-charge for all high-risk children 
throughout Poland [6]. Since 2006, Kielce has 
been the only city in Poland to provide univer-
sal PCV vaccination without charge to resident 
children [10, 11]. PPSV23 vaccination coverage 
in adults 65 years of age and older in Poland has 
been minimal (about 1%) [12].
Poland has little published information on 
the burden of CAP [1]. Prior investigation of the 
burden of pneumococcal disease in Poland has 
focused on children [13, 14] or has largely ad-
dressed patients with meningitis [15] due to more 
widespread use of microbiology culture for this 
condition [13–16]. Studies conducted in Kielce 
utilized National Health Fund data among hospi-
talized and non-hospitalized patients to estimate 
the incidence of pneumonia before and after the 
introduction of universal PCV7 vaccination in 2006 
[10, 11]. Prior to the introduction of widespread 
PCV7 vaccination (2004–2005) the investigators 
found an incidence of pneumonia of 4.94 per 1000 
persons in all ages in Kielce [10]. Compared to 
post-vaccine years (2007–2010), significant declines 
in pneumonia incidence occurred in children 0–2 
years, as well as older age groups [11]. Replication 
of these results in other parts of Poland is lacking.
Because the burden of pneumococcal 
disease is not well characterized in Poland and 
given the absence of widespread pneumococcal 
vaccination in all age groups, the main goal of 
this epidemiological study was to characterize 
the burden of pneumonia in two Polish county 
populations between 2006 and 2008. Hospital 
visits characteri zed by International Classifica-
tion of Diseases and Related Health Problems 10th 
Revision (ICD-10) codes were used to measure 
the burden of pneumonia, an approach similar 
to several prior studies [2, 5, 17–20].
Material and methods
Study design
A retrospective study was conducted using 
data from electronic administrative databases at 
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two Polish county hospitals, Chrzanów County 
Hospital and Inowrocław County Hospital. As the 
only hospitals within their counties, primary care 
physicians refer their patients to these hospitals 
and residents are likely to seek treatment at these 
hospitals for emergency care. As health insurance 
is mandatory in Poland, virtually all residents 
have access to health care. 
The main study objective was to quantify 
the hospitalization rate of pneumonia in the two 
study populations utilizing ICD-10 codes. Secon-
dary objectives included describing the mortality 
rate and quantifying other available data related 
to the burden of this disease, i.e., diagnostic data 
and length of hospital stay.
Study subjects
Cases included patients hospitalized at 
Chrzanów County Hospital and Inowrocław 
County Hospital from 2006–2008, who were 
residents of Chrzanów and Inowrocław coun-
ties at the time of hospitalization and assigned 
a diagnosis of pneumonia in accordance with the 
ICD-10 code list provided in Table 1. 
 Methods
For each case with an admission date from 
2006–2008, information was collected on demo-
graphics (age and sex), mortality, and length of 
hospital stay (LOS). Duplicate and non-incident 
observations were excluded from the hospitali-
zation rate analysis (n = 198). Hospitalizations 
were considered duplicates if the same patient 
had identical information for multiple visits. Visits 
were considered non-incident if the same patient 
had < 30 days between two or more given visits. 
Non-incident visits were included in calculations 
for the LOS and mortality. 
Data were aggregated by year of admission, 
sex, and age category for each site. Yearly pop-
ulation information by county was ob tained 
from the Polish Central Statistical Office website 
(http://www.stat.gov.pl). Additional informa-
tion on chest X-ray results and cultures was 
available at Inowrocław County Hospital, but 
not at Chrzanów County Hospital, in the form 
of electronic discharge cards. This sub-analy-
sis was used to provide further evidence on 
disease burden. The primary reader abstracted 
information on a random sample of 250 cases. 
After data cleaning, 215 cases were included 
for subsequent calculations. In addition, the 
secondary reader performed independent vali-
dation on 50 cases.




J12: Viral pneumonia, not elsewhere classified
 J12.0 Adenoviral pneumonia
 J12.1 Respiratory syncytial virus pneumonia
 J12.2 Parainfluenza virus pneumonia
 J12.8 Other viral pneumonia
 J12.9 Viral pneumonia, unspecified
J13: Pneumonia due to Streptococcus pneumoniae
J14: Pneumonia due to Haemophilus influenzae
J15: Bacterial pneumonia not elsewhere classified
 J15.0 Pneumonia due to Klebsiella pneumoniae
 J15.1 Pneumonia due to Pseudomonas
 J15.2 Pneumonia due to Staphylococcus
 J15.3 Pneumonia due to Streptococcus, group B
 J15.4 Pneumonia due to other Streptococci
 J15.5 Pneumonia due to Escherichia coli
 J15.6 Pneumonia due to other aerobic Gram-negative 
bacteria
 J15.7 Pneumonia due to Mycoplasma pneumoniae
 J15.8 Other bacterial pneumonia
 J15.9 Bacterial pneumonia, unspecified
J16: Pneumonia due to other infectious organisms,  
not elsewhere classified
 J16.0 Chlamydial pneumonia
 J16.8 Pneumonia due to other specified infectious  
organisms
J17: Pneumonia in diseases classified elsewhere
 J17.0 Pneumonia in bacterial diseases classified else-
where
 J17.1 Pneumonia in viral diseases classified elsewhere
 J17.2 Pneumonia in mycoses
 J17.3 Pneumonia in parasitic diseases
 J17.8 Pneumonia in other diseases classified elsewhere
J18: Pneumonia, organism unspecified
 J18.0 Bronchopneumonia, unspecified
 J18.1 Lobar pneumonia, unspecified
 J18.2 Hypostatic pneumonia, unspecified
 J18.8 Other pneumonia, organism unspecified
 J18.9 Pneumonia, unspecified
This study was categorized as exempt from 
review by the ethics committee by the Regional 
Chamber of Physicians in Bydgoszcz, and ap-
proved by the ethics committee Regional Chamber 
of Physicians in Kraków.
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Analysis
Hospitalization incidence rates per 1000 
persons were calculated as case number divided 
by corresponding at-risk population number and 
multiplied by 1000. Assuming a Poisson distri-
bution, 95% confidence intervals (CIs) were cal-
culated for all hospitalization rate estimates [21]. 
In-hospital mortality rates (in percentages) 
were calculated by dividing the total number of 
deaths by the hospitalized cases of that disease 
and multiplied by 100. Deaths could occur during 
incident hospitalization or during a non-incident 
hospitalization among patients who had re-hospi-
talizations for the same condition within 30 days. 
So both incident and non-incident cases were 
included in in-hospital mortality rate calculation. 
Continuity-adjusted 95% CIs using the Wilson 
method [22] were provided for all in-hospital 
mortality rates. 
For LOS, medians, as well as the 25th and 
75th percentile values, were calculated by strata. 
The Kruskal-Wallis and Mann-Whitney tests were 
utilized to statistically test differences between 
two or more relevant groups on the distribution 
for this dimension. A two-sided threshold of 0.05 
was utilized to determine statistical significance.
From X-ray and culture data abstracted in 
Inowrocław, the proportions of pneumonia in 
patients with an abnormal chest X-ray with or 
without lobar consolidation, and/or pleural 
effusion among those with a chest X-ray per-
formed, were also calculated. The percentage 
of cultures positive for S. pneumoniae was 
calculated as the total number of readings that 
were positive for S. pneumoniae divided by the 
number of inpatients reviewed with a culture 
performed on any sterile specimen (e.g. blood, 
cerebrospinal fluid, pleural fluid).
Two analysts independently analyzed the 
data, one using SAS version 9.1.3 (SAS Institute 
Inc., Cary, NC, USA) and one using STATA version 
11 (Statcorp, College Station, TX, USA). During 
validation, the two sets of results were compared 
with subsequent resolution of discrepancies. 
Results
The total county populations over the 3-year 
study period were 383 644 and 493 727 for Chrza-
nów County Hospital and Inowrocław County 
Hospital, respectively. In this period, a total of 
1444 and 2956 incident pneumonia cases were 
identified from Chrzanów County Hospital and 
Inowrocław County Hospital, respectively. For 
ICD-10 code J13 (pneumonia due to S. pneumo-
niae), there were three cases in Chrzanów and 
zero cases in Inowrocław. In both study sites 
combined, there were 417 deaths.
Hospitalizations rates
Overall, the hospitalization rate in Chrza-
nów County (3.76; 95% CI 3.57–3.96) was lo-
wer than in Inowrocław County (5.99; 95% CI 
5.77–6.21). The hospitalization rate for the two 
sites combined was 5.01 per 1000 persons (95% 
CI 4.87–5.17). Males had consistently higher 
pneumonia hospitalization rates across sites 
and years (Table 2). Age patterns demonstrated 
the highest hospitalization rate among inpatients 
aged 0–4 years (30.77; 95% CI 29.06–32.55) fol-
lowed by those aged ≥ 75 years (25.39; 95% CI 
24.01–26.83) (Table 2). This finding was con-
sistent for all study years (Fig. 1) and by years 
across sites (data not shown). 
 In-hospital mortality rates 
In-hospital mortality rates were 10.53 (95% 
CI 9.05–12.22) in Chrzanów County and 8.96 
(95% CI 7.99–10.05) in Inowrocław County. The 
overall in-hospital mortality rate was 9.48 per 
100 persons (95% CI 8.65–10.38). There were 
similar in-hospital mortality rates for males and 
females at both sites for all study years (Table 3). 
The in-hospital mortality rates increased by age 
group with the highest in those aged ≥ 75 years 
for all study years (Fig. 2). These patterns held 
irrespective of study site. 
Length of stay (LOS)
Median LOS was slightly longer in Chrza-
nów County Hospital compared with Inowro-
cław County Hospital for incident pneumonia 
cases (9 days compared with 8 days; p < 0.001). 
Cases at both sites had a combined median LOS 
of 8 days (Table 4). Males had significantly hi-
gher LOS in Inowrocław, but not in Chrzanów 
(p = 0.04; Table 4). Comparing the distribution 
of LOS by age, there was significant variation 
(p = 0.0001). In general, those aged <15 years 
had a significantly lower LOS than those aged 
>15 years (p < 0.001). 
Clinical data
In Inowrocław County Hospital, chest X-rays 
were commonly performed (205 of the 215 pa-
tients, 95.35%), and nearly all X-rays were de-
scribed as abnormal (200 of 205, 97.56%). Lobar 
consolidation or pleural effusion was rarely iden-
tified as the finding for abnormal chest X-rays (1 of 
205, 0.49%). In Poland, other infiltrates consistent 
Rafal Harat et al., Hospitalized pneumonia in 2 counties
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Table 2.  Pneumonia hospitalization rates by admission year, county, sex, and age group in Chrzanów County Hospital and 
Inowrocław County Hospital, Poland, January 1, 2006 through December 31, 2008 





Hospitalization rate per 
1000 persons (95% CI)




Hospitalization rate per 
1000 persons (95% CI)
Year 2006 532 128 093 4.15 (3.81, 4.52) 832 164 943 5.04 (4.71, 5.40)
2007 501 127 859 3.92 (3.58, 4.28) 1213 164 571 7.37 (6.96, 7.80)
2008 411 127 692 3.22 (2.91, 3.55) 911 164 213 5.55 (5.19, 5.92)
Countya Total 1444 383 644 3.76 (3.57, 3.96) 2956 493 727 5.99 (5.77, 6.21)
Sexa Male 785 185 875 4.22 (3.93, 4.53) 1627 239 007 6.81 (6.48, 7.15)
Female 659 197 769 3.33 (3.08, 3.60) 1329 254 720 5.22 (4.94, 5.51)
Age, 
yearsa
0–4 365 16 541 22.07 (19.86, 24.45) 845 22 789 37.08 (34.62, 39.67)
5–14 98 37 648 2.60 (2.11, 3.17) 171 53 728 3.18 (2.72, 3.70)
15–49 135 196 680 0.69 (0.58, 0.81) 212 257 798 0.82 (0.72, 0.94)
50–64 195 77 240 2.52 (2.18, 2.90) 415 99 139 4.19 (3.79, 4.61)
65–74 237 32 025 7.40 (6.49, 8.41) 465 34 084 13.64 (12.43, 14.94)
≥75 414 23 510 17.61 (15.95, 19.39) 848 26 189 32.38 (30.24, 34.63)
aAggregates 2006–2008
 Figure 1. Hospitalization rates of pneumonia cases by admission year and age group in Chrzanów and Inowrocław County Hospitals, Poland, January 1, 
2006 through December 31, 2008
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Table 3.  In-hospital mortality rate (IHMR) per 100 patients hospitalized with pneumonia by admission year, county, sex, 
and age group in Chrzanów County Hospital and Inowrocław County Hospital, Poland, January 1, 2006 through 
December 31, 2008











IHMR per 100 patients
 (95% CI)
Year 2006 48 532 9.02 (6.87, 11.76) 73 832 8.77 (7.04, 10.89)
2007 39 501 7.78 (5.75, 10.46) 94 1213 7.75 (6.37, 9.39)
2008 65 411 15.82 (12.61, 19.66) 98 911 10.76 (8. 91, 12.94)
Countya Total 152 1444 10.53 (9.05, 12.22) 265 2956 8.96 (7.99, 10.05)
Sexa Male 86 785 10.96 (8.96, 13.33) 161 1627 9.90 (8.54, 11.44)
Female 66 659 10.02 (7.95, 12.54) 104 1329 7.83 (6.50, 9.39)
Age, 
yearsa
0–4 0 365 0 (0, 1.04) 0 845 0 (0, 0.45)
5–14 0 98 0 (0, 3.77) 0 171 0 (0, 2.20)
15–49 9 135 6.67 (3.55, 12.18) 15 212 7.08 (4.33, 11.34)
50–64 12 195 6.15 (3.55, 10.45) 53 415 12.77 (9.90, 16.33)
65–74 33 237 13.92 (10.09, 18.91) 59 465 12.69 (9.97, 16.02)
≥ 75 98 414 23.67 (19.83, 28.00) 138 848 16.27 (13.94, 18.91)
aAggregates 2006–2008
Figure 2. In-hospital mortality rates for pneumonia cases by admission year and age group in Chrzanów and Inowrocław County Hospitals, Poland, 
January 1, 2006 through December 31, 2008
Rafal Harat et al., Hospitalized pneumonia in 2 counties
435www.pneumonologia.viamedica.pl
with pneumonia are commonly noted, although 
we did not collect these data. In terms of the 
culture results, very few cultures were reported 
as performed (7 of 215, 3.26%) and none was 
recorded as positive for S. pneumoniae (0 of 7). 
Discussion
For Chrzanów and Inowrocław counties, the 
overall hospitalization rates of pneumonia were 
3.76 and 5.99 per 1000 persons, respectively. 
These rates were within the range of CAP rates 
found in other European studies [23–25] though 
there were differences in case definitions. The 
higher hospitalization rates in Inowrocław rela-
tive to Chrzanów County may be associated with 
the lower socioeconomic status of residents of 
Inowrocław County compared with Chrzanów 
County, given prior evidence of a relationship 
between low socioeconomic status and higher 
pneumonia incidence [26]. In addition, variable 
patterns in hospitalization could contribute to 
county differences. If there was a higher thresh-
old for inpatient treatment of pneumonia in 
Chrzanów, due to greater willingness or capacity 
to manage patients in the community, then that 
could lead to its lower hospitalization rate. 
Men consistently had higher hospitalization 
rates relative to women in Poland likely due to 
an increased number of risk factors including 
smoking, alcohol, and toxic occupational expo- 
sures [27, 28]. Consistent with results seen in other 
countries [1, 20, 29] the youngest and old est age 
groups had the highest hospitalization rates for 
pneumonia. In adults aged ≥ 65 years, the pneumo-
nia rate of 18.41 per 1000 persons in Kielce before 
widespread PCV vaccination [10] was between the 
rate (for this age group) of 11.72 in Chrzanów and 
21.78 per 1000 persons in Inowrocław. According 
to a co-author, the data in Kielce [10] included both 
hospital and primary care visits. 
The in-hospital mortality rate for adults aged 
≥ 18 years with pneumonia in this study, 14.16 per 
100 persons, was higher than that seen in other 
studies [30, 31]. Nevertheless, this slightly higher 
in-hospital mortality rate could be a measurement 
artifact related to the inability of this study to 
exclude nosocomial pneumonia infections, which 
often have higher mortality rates [32]. The highest 
in-hospital mortality rate was seen in 2008 de-
spite lower hospitalizations for disease during this 
period. One potential explanation for variations in 
in-hospital mortality rates by year could be linked 
to the proportion of those aged ≥ 75 years among 
cases, which was highest (31.85%) in 2008, and 
lower in 2006 and 2007 (26.39% and 28.06%, 
respectively). Between genders, mortality rates 
were similar despite differences in hospitalization 
rates observed between males and females. The 
highest pneumonia mortality rates were in those 
Table 4. Median length of stay for hospitalized pneumonia cases by admission year, county, sex, and age group in Chrza-
nów County Hospital and Inowrocław County Hospital, Poland, January 1, 2006 through December 31, 2008
Chrzanów County Hospital Inowrocław County Hospital
No. of cases Median length 
of stay, days
25th, 75th  
percentile
No. of cases Median length 
of stay, days
25th, 75th  
percentile
Year 2006 532 9 8, 12 832 8 7, 9
2007 501 9 8, 12 1213 8 6, 9
2008 411 10 8, 15 911 8 5, 9
Countya Total 1444 9 8, 13 2956 8 6, 9
Sexa Male 785 9 8, 13 1627 8 6, 9
Female 659 9 8, 13 1329 8 6, 9
Age, yearsa 0–4 365 8 8, 10 845 7 5, 8
5–14 98 8 8, 10 171 6 4, 8
15–49 135 9 8, 12 212 8 6, 10
50–64 195 10 8, 14 415 8 8, 12
65–74 237 10 8, 15 465 8 8, 10
≥75 414 10 8, 15 848 8 7, 10
aAggregates 2006–2008
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aged ≥ 75 years, similar to patterns described in 
other developed countries such as Germany [18], 
England [1], and Spain [3]. The in-hospital mor-
tality rate was lower in Inowrocław especially in 
the oldest age groups, although this could be lin-
ked to higher hospitalization rates in Inowrocław 
among less severely ill patients, thereby lowering 
the mortality rates. Given the lack of clinical 
data for pneumonia patients in this study, there 
is no way to systematically evaluate patterns of 
hospitalization.
As each day of hospital admission requires 
considerable human and administrative resour-
ces as well as accrued direct costs, LOS provides 
a proxy for the burden of specified diseases on the 
healthcare system. Comparing the median LOS 
for pneumonia patients seen in this study to other 
countries, it was greater than the median LOS of 
6 days found in a Canadian hospital-based study 
from 1991–2001 among patients aged ≥ 15 years 
[17], and less than the average LOS of 10.8 days 
in a study in German hospitals among adults aged 
≥ 18 years with CAP [30]. There was no difference 
in LOS between males and females overall, simi-
lar to research in Canada which demonstrated no 
difference in LOS for CAP patients based on sex 
[17]. There was variability in LOS by age with 
patients aged < 15 years being more likely to 
have a shorter LOS. 
According to co-investigators at study hospi-
tals, adult patients hospitalized with pneumonia 
in almost all cases have chest X-rays performed 
and receive diagnoses of pneumonia only when 
confirmed by chest X-ray. In contrast, in children 
diagnoses may be based on clinical symptoms 
only. Laboratory data using electronic hospital 
discharge cards were examined in Inowrocław 
County Hospital only. Consistent with investi-
gator statements, chest X-rays were frequently 
performed and almost always had abnormal 
findings, although these were rarely recorded 
as lobar consolidation or pleural effusion. Of 
note, the information recorded in the hospital 
discharge cards was not recorded in a systema-
tic or comprehensive manner. The low rates of 
cultures for pneumonia patients observed in 
this study in Inowrocław County Hospital were 
consistent with the limited performance of cul-
tures for pneumonia patients (approximately 10% 
according to the study investigators), although 
there could also be incomplete reporting by the 
doctors completing this information. It is worth 
noting that difficulties in identifying the etiologic 
agent in pneumonia cases in Poland have been 
documented in previous studies and are believed 
to be due to economic, logistical, and technical 
issues [5, 10]. Therefore, the low rates of culture 
are not unusual for the setting, and diagnoses 
of pneumonia may be pneumococcal in nature 
although not identified or recorded as such with 
ICD-10 codes.
A recent study in Kielce, Poland has de-
monstrated not only a decrease in pneumonia 
incidence for those vaccinated but also herd ef-
fects of the vaccinations in non-vaccinated older 
age groups after widespread PCV7 vaccination 
[11], paralleling similar findings in the United 
States and Australia [2, 33]. In 2011 in Poland, 
13-valent PCV (PCV13) replaced PCV7 for use in 
high-risk children. In addition, in 2013, PCV13 
was recommended in place of PPSV23 for adults 
> 65 years and children (> 2 years) and adults at 
risk [8].  In children, there is emerging evidence 
that PCV13 is reducing the number of cases of 
IPD involving covered serotypes [34, 35].  For 
example, in the US following the introduction 
of PCV13, invasive pneumococcal infections de-
creased 42% in 8 hospitals for children in 2011 
compared to years 2007–2009 [34]. For adults, 
preliminary evidence for the effectiveness of 
PCV13 was based on immunogenicity studies that 
compared antibody responses for the new vaccine 
with PPSV23 [36]. Results from a randomized, 
placebo-controlled trial of the clinical efficacy 
of PCV13 against pneumococcal pneumonia in 
adults 65 years and older in The Netherlands are 
not yet available [36, 37].
This study had several strengths. Available 
data were used which curtails the time and expen-
se of conducting prospective surveillance. This 
study also removed non-incident and duplicate 
cases from the calculations of hospitalization 
rates because re-hospitalizations for the same 
episode of illness have the potential to inflate 
the hospitalization rate. A threshold of 30 days 
was used based upon prior work, which defined 
incident invasive pneumococcal disease cases 
as occurring ≥4 weeks (approximately 30 days) 
apart [38]. This was a conservative approach but 
prevented overestimation due to readmission for 
the same disease episode.
This study also had limitations common to 
studies conducted with retrospective administra-
tive data. The application of ICD-10 codes may 
not be valid or reliable as it is often influenced 
by reimbursement systems; although evidence of 
this pattern has been mixed [39, 40]. There were 
changes in the approach for coding diagnoses 
in August 2008 but these were not anticipa-
ted to substantially affect hospitalizations for 
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pneumonia. For in-hospital deaths, there was 
no verification of pneumonia as the cause of 
death. Furthermore, based on standard of care, 
there was limited performance of cultures, and 
resultant utilization of ICD-10 codes was mostly 
non-specific with respect to etiology (i.e., there 
were only three cases coded as pneumococcal 
disease). In addition, because this study only 
included inpatients it underestimated the true 
burden of pneumonia in the populations of inter-
est. Also, county differences in hospitalization 
rates could be influenced by selection factors as 
cases were only counted when hospitalized, and 
any differences in capacity to diagnose and treat 
pneumonia patients outside the hospital could 
alter this count. The ICD-10 codes also did not 
allow for the exclusion of nosocomial infections 
as no codes specific to this diagnostic category 
exist. Although the two study hospitals are the 
only acute care hospitals serving their respective 
counties, there was no evidence that all residents 
attended the county hospitals for treatment of the 
diseases of interest. Given this, the current study 
may underestimate hospitalization rates if coun-
ty residents sought care outside the county for 
pneumonia. Furthermore, as this study was only 
conducted in two counties in Poland the results 
cannot be generalized to the country as a whole.
Conclusions
In summary, this study measured multiple 
indicators of the burden of pneumonia in two 
Polish hospitals serving separate countywide pop-
ulations, and suggested considerable hospitaliza-
tion for pneumonia in these counties, especially 
for those aged 0–4 years and ≥ 75 years. Future 
public health interventions aimed at these age 
groups might improve disease outlook.
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